How to Choose a CDMO for Formulation Development

The short answer: Choosing a CDMO for formulation development is less about manufacturing capacity and more about formulation R&D depth matched to your molecule's actual problem. Confirm the partner has solved your class of challenge before — poor solubility, bioavailability enhancement, a modified-release or sterile dosage form, a difficult stability profile — with named technologies and case data, not a capability list. Then check the two things that decide whether development translates into supply: a real analytical development function that will transfer validated methods, and a demonstrated path from lab formulation to GMP clinical (and commercial) batches on equipment you can scale into. Weigh that capability fit alongside the usual compliance and quality screen.

Formulation development is where a promising drug substance becomes a usable drug product — or stalls. It is also the stage where the wrong partner is most expensive, because a formulation that cannot be scaled, analysed reproducibly, or defended to a regulator has to be redone, and every month of delay is a month of burn. This guide covers how to select a CDMO for that work specifically.

What formulation development actually requires

Formulation development is not a single service. Before you evaluate vendors, be precise about which of these your program needs, because CDMOs specialise:

• Preformulation and physicochemical characterisation — solubility, pKa, polymorphism, particle size, hygroscopicity, and permeability that determine what is even feasible.
• Formulation design for a target dosage form — immediate or modified-release oral solids, liquids and suspensions, sterile injectables, inhalation, or topical/transdermal.
• Bioavailability enhancement for poorly soluble compounds — amorphous solid dispersions (spray drying, hot-melt extrusion), lipid-based systems, particle-size reduction, or salt/co-crystal selection.
• Analytical development — the methods that prove the formulation does what it should, developed in parallel and transferable to QC.
• Scale-up and clinical manufacturing — turning a bench formulation into GMP batches for the clinic.

A CDMO that is excellent at one of these is not automatically credible at the others. The single most common sourcing error is buying a capacity story when the program needs a science story.

1. Match the CDMO to your molecule's real problem

Start from the molecule, not the vendor. Roughly the majority of new small-molecule candidates have a solubility or bioavailability limitation, and the technology that solves it is the axis on which you should select:

• A BCS Class II/IV poorly soluble compound needs demonstrated experience in the specific enhancement technology you are likely to use — amorphous spray-dried dispersions, hot-melt extrusion, lipid formulations, or nanomilling. Ask which they have taken into the clinic, not which they own.
• A modified-release requirement needs a partner with a release-technology platform and the analytical capability to characterise the release mechanism, not just compress a tablet.
• A sterile or biologic drug product moves you into a different qualification entirely — fill–finish, container-closure, and aseptic experience — closer to the questions in choosing a CDMO for ADCs than to an oral-solids project.

Ask for anonymised case studies in your dosage form and your solubility class, and for the names of the enabling technologies they have actually filed with. "We can do spray drying" is a capability; "we have taken four amorphous dispersions through Phase I" is evidence.

2. Assess formulation R&D depth, not just the plant

A tour of a manufacturing suite tells you about capacity, not about whether the CDMO can invent your formulation. Probe the development function:

• Scientific staff and track record — the size and seniority of the formulation and analytical groups, and their publication or filing history in your area.
• Design-of-experiments and QbD — whether formulation and process are developed as a designed space, which is what a modern CMC dossier expects, or by trial and error that will not survive review.
• Material-sparing early work — the ability to make real decisions on milligrams of API when your drug substance is scarce and expensive.

The output of good development is a formulation and a defensible rationale for it. A partner who cannot explain why they chose an approach will not be able to defend it to a regulator, and you will inherit that gap.

3. Insist on real analytical development

Formulation and analysis are one job, not two. A formulation you cannot measure reproducibly is not a formulation you can file. Confirm the CDMO has an analytical-development group that will:

• Develop and validate stability-indicating methods alongside the formulation, not after it.
• Handle the impurity, dissolution, and content-uniformity work your dosage form requires.
• Transfer those methods cleanly to QC and, later, to a commercial site — method transfer is a frequent and underestimated failure point in a technology transfer.

If analytical development is thin or outsourced to a third party, timelines and accountability both fragment.

4. Check the path from formulation to GMP supply

Development only pays off if it becomes clinical, then commercial, supply. Before contracting, understand the whole path:

• Scale-up feasibility — is the bench formulation designed on equipment and principles that scale, or on a technique that will not survive tenfold volume?
• GMP clinical manufacturing — can the same organisation make your Phase I/II material under GMP, so you are not re-transferring the moment you have a formulation that works?
• A credible commercial route — either in-house commercial capacity or a clean tech transfer to one, so you are not forced into a disruptive change of partner at the worst moment.

A one-stop development-through-commercial CDMO reduces transfer risk; a development-only specialist may give you deeper science but a transfer to manage later. Neither is wrong — but decide deliberately, and screen every candidate's site the same way you would any supplier, against its live FDA compliance record.

Common pitfalls

• Buying capacity when you need science. A large plant does not formulate a difficult molecule; a formulation group does.
• Ignoring analytical development until the formulation is "done," then discovering it cannot be measured to file.
• Selecting a technology the CDMO owns rather than the one your molecule needs — vendors steer toward their installed base.
• No scale-up plan, so a formulation that works at the bench cannot be made in the clinic without redesign.

Where this fits

Formulation-development selection is one half of drug-product sourcing; the manufacturing-partner screen is the other, and both run on the same axes — capability fit, analytical rigour, GMP status, and regulatory record. For the full selection framework see our CDMO selection checklist, and if you are still deciding whether you need development capability at all or only manufacturing, start with CRO vs CDMO vs CMO.

PharmaTek links CDMO and drug-product capabilities to each company's regulatory and FDA compliance record across a directory of 22,000+ pharmaceutical companies, so a formulation-development shortlist can be screened for compliance at the same time it is built for capability.

Frequently asked questions

What should I look for in a CDMO for formulation development? Formulation R&D depth matched to your molecule's specific problem — solubility, bioavailability, dosage form, stability — evidenced by named enabling technologies taken into the clinic, not a capability list. Alongside that, a real analytical-development function that will develop and transfer validated methods, and a demonstrated path from bench formulation to GMP clinical and commercial supply.

How is a formulation-development CDMO different from a manufacturing CMO? A formulation-development CDMO designs the drug product — it solves the scientific problem of turning a drug substance into a stable, bioavailable, manufacturable dosage form. A CMO manufactures to an already-defined process. Selecting a CDMO weights scientific and analytical depth; selecting a CMO weights capacity, cost, and GMP execution.

How do I choose a CDMO for a poorly soluble (BCS Class II/IV) compound? Select on the bioavailability-enhancement technology your molecule is likely to need — amorphous solid dispersion (spray drying or hot-melt extrusion), lipid-based systems, particle-size reduction, or salt/co-crystal selection — and confirm the CDMO has taken that specific technology into the clinic, with case data, not just installed equipment.

Why does analytical development matter when choosing a formulation CDMO? Because a formulation you cannot measure reproducibly cannot be filed. Stability-indicating, dissolution, impurity, and content-uniformity methods have to be developed alongside the formulation and transferred cleanly to QC. Thin or outsourced analytical development fragments timelines and accountability and is a common late-stage failure point.

Should one CDMO do both formulation development and commercial manufacturing? A single development-through-commercial partner reduces technology-transfer risk and avoids changing suppliers at a critical moment. A development-only specialist may offer deeper science but leaves you a transfer to manage. Both are valid — decide deliberately based on your molecule's difficulty and your tolerance for a later transfer.

---

Building a formulation-development shortlist? Explore the supplier directory or book a demo to screen candidates against live FDA compliance data.